May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Heme Oxygenase–2 (HO–2) Knockout Mice Display Impaired Corneal Wound Healing and Marked Corneal Neovascularization
Author Affiliations & Notes
  • M. Laniado–Schwartzman
    Pharmacology,
    New York Medical College, Valhalla, NY
  • A. Mezentsev
    Pharmacology,
    New York Medical College, Valhalla, NY
  • F. Seta
    Pharmacology,
    New York Medical College, Valhalla, NY
  • M.W. Dunn
    Ophthalmology,
    New York Medical College, Valhalla, NY
  • N.G. Abraham
    Pharmacology,
    New York Medical College, Valhalla, NY
  • K. Gronert
    Pharmacology,
    New York Medical College, Valhalla, NY
  • Footnotes
    Commercial Relationships  M. Laniado–Schwartzman, None; A. Mezentsev, None; F. Seta, None; M.W. Dunn, None; N.G. Abraham, None; K. Gronert, None.
  • Footnotes
    Support  NIH Grants EY06513 & HL34300
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3619. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Laniado–Schwartzman, A. Mezentsev, F. Seta, M.W. Dunn, N.G. Abraham, K. Gronert; Heme Oxygenase–2 (HO–2) Knockout Mice Display Impaired Corneal Wound Healing and Marked Corneal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3619.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Heme oxygenases (HO–1 and HO–2) constitute an intrinsic cytoprotective and anti–inflammatory system in cells and tissues. This cytoprotection is attributed to the ability of HO to inhibit expression of inflammatory cytokines and proteins as well as to its products bilirubin (a powerful antioxidant) and CO (a vasodilator and anti–apoptotic factor). Coexisting with the HO system in the corneal epithelium is the cytochrome P450 (CYP) dependent pathway that converts arachidonic acid into two potent inflammatory mediators that constitute a critical part of the ocular surface inflammatory response. Induction of HO activity substantially attenuates the ocular surface inflammatory response and the associated corneal changes while enhancing cell survival by decreasing CYP activity. The present study was set to examine whether a deficiency in the ability to express this system impairs corneal recovery following injury. Methods:We used HO–2 knockout mice. Injury was performed by removing the epithelium from corneas using an Algerbrush. Wound healing, re–epithelialization, opacity and neo–vascularization were assessed by slit lamp vital microscopy. Corneas were collected at different time after injury (1–14 days) and inflammatory markers quantified by ELISA, mass spectrometry, and RT–PCR. Results:This injury produced a consistent and predictable inflammatory response including injection, neutrophil infiltration and neovascularization and a time dependent re–epithelization with full wound closure by 4 days. The results clearly indicate that HO–2 deficiency results in an aberrant inflammatory response including delayed wound closure, ulceration, persistent neovascularization and perforation. This response was associated with inability to upregulate HO–1, increased expression of inflammatory genes including CYP, COX–2 and IL–12, and increased production of inflammatory mediators such as PGE2 and the angiogenic CYP–derived eicosanoid, 12–HETrE. Conclusions:These results demonstrate that the HO–2 knockout mice experience an exaggerated uncontrolled chronic inflammation and suggest a novel role for HO–2 in providing cytoprotection, a role previously assigned primarily to the HO inducible form, HO–1. Better understanding of the complex heme–heme oxygenase system may result in novel tools to combat diverse conditions, such as inflammation.

Keywords: inflammation • wound healing • eicosanoids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×